Nomura Asset Management Co. Ltd. Has $2.90 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Nomura Asset Management Co. Ltd. boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,694 shares of the medical research company’s stock after buying an additional 102 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Charles River Laboratories International were worth $2,897,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of CRL. Wellington Management Group LLP boosted its position in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. Norges Bank bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at $98,886,000. Raymond James Financial Inc. acquired a new position in Charles River Laboratories International during the fourth quarter worth $42,776,000. Cooke & Bieler LP lifted its stake in Charles River Laboratories International by 42.1% in the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock valued at $78,781,000 after acquiring an additional 126,372 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares during the period. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

CRL has been the subject of several recent analyst reports. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Barclays reduced their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 18th. Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their price target for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $149.30 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $142.76 and a fifty-two week high of $264.71. The company has a market cap of $7.63 billion, a price-to-earnings ratio of 995.33, a PEG ratio of 4.54 and a beta of 1.45. The stock has a fifty day moving average price of $163.57 and a 200-day moving average price of $181.69.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.46 earnings per share. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO James C. Foster bought 6,075 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).